IPF Cough: Opioid-Based Approach Tested
-
By
January 28, 2026
-
3 min
-
1
Nalbuphine is an oral κ-opioid receptor agonist evaluated for chronic cough in IPF.
-
2
Phase 2b trial conducted at 52 sites across 10 countries.
-
3
Significant reductions in cough frequency: 60% with 108 mg dose vs 17% placebo.
-
4
Improvement in cough severity and quality of life for higher doses.
-
5
Common mild adverse events included nausea, vomiting, dizziness.
-
6
Key limitation: only 6 weeks of treatment duration.
-
7
Further studies required to confirm findings in larger populations.
-
A phase 2b randomized clinical trial evaluated the efficacy of nalbuphine, an oral κ-opioid receptor agonist, in treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Conducted across 52 sites worldwide, the study showed significant dose-dependent reductions in cough frequency after 6 weeks, with the highest dose achieving a 60% reduction compared to placebo. Improvements were also noted in cough severity and quality of life for higher dose groups. Despite mild adverse effects, findings highlight the need for further large-scale studies.
-
1
Nalbuphine is an oral κ-opioid receptor agonist evaluated for chronic cough in IPF.
-
2
Phase 2b trial conducted at 52 sites across 10 countries.
-
3
Significant reductions in cough frequency: 60% with 108 mg dose vs 17% placebo.
-
4
Improvement in cough severity and quality of life for higher doses.
-
5
Common mild adverse events included nausea, vomiting, dizziness.
-
6
Key limitation: only 6 weeks of treatment duration.
-
7
Further studies required to confirm findings in larger populations.
Listen Tab content
